156100 — L&K Biomed Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for L&K Biomed Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	19,356	15,373	19,767	29,905	36,092
Cost of Revenue
Gross Profit	13,496	7,461	14,889	25,765	30,250
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	26,044	31,395	33,377	42,583	33,395
Operating Profit	-6,688	-16,022	-13,610	-12,678	2,697
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-9,239	-8,897	-16,299	-6,468	9,815
Provision for Income Taxes
Net Income After Taxes	-10,672	-13,646	-16,233	-5,239	9,151
Minority Interest
Net Income Before Extraordinary Items
Net Income	-10,715	-9,669	-13,625	-1,867	9,743
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,715	-9,669	-13,625	-1,867	9,743
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-640	-633	-892	474	458
Dividends per Share